Replies to post #268 on MEI Pharma, Inc. (MEIP)

[value1008]

It looks like MEIP put in a bottom two days ago with that intraday slide to 3.61, slightly above the intraday 3.57 in Dec. after the share-offering. With this second, slightly higher bottoming, and topline data results coming in March, and the bullish PTs of $14-$16 from analysts Brim at CantorFitz and Aschoff at Brean Cap, and big positions by OrbiMed and Point72 Asset Mgmt, this one looks good to head back up to the $7/$8 level where it traded before the offering. A bit of resistance here at 20dma presently at 3.99, with likely some more resistance at 50dma (4.81) and then 200dma (6.44).

Lots of blue sky above that if results are good as expected.

Btw, BofA/MLynch led the share-offering in Dec.; any silent period for analysts would now be over, so at some point i expect to see them initiate coverage with a bullish note; even a PT of just $10 or $12 would zoom this up considerably.

[chmcnfunds]

Maybe an number of factors. Now 6 weeks since the offering at $4.00 and down ~6%. Chart showing there is some pent up buying pressure so now almost all technical indicators except SAR are positive. Was an insider buy a week ago, a positive SA article earlier this week, and expected data just over a month from now:

Intermediate and High Risk MDS

Similar to the results seen in AML, Pracinostat has been just as impressive in treating MDS. The hypomethylation agent Azacitidine is already FDA approved for treating intermediate and high-risk MDS, which showed a clinical response rate (complete and partial) of 16% in Phase III clinical trials and an overall survival benefit. In the pilot Phase II trial combining Pracinostat with Azacitidine there was an impressive 90% complete response rate (9/10 patients). This data led to a randomized Phase II trial at 24 sites evaluating 102 patients randomized 1:1 with Pracinostat and Azacitidine or Placebo and Azacitidine with a primary endpoint of complete response. The data from this trial is expected to be released in March 2015, which would be a significant catalyst if positive. Perhaps even more impressive is the data that was released on December 22, 2014 from the Phase II clinical trial where Pracinostat is being evaluated in combination with a hypomethylation agent in patients that have previously failed hypomethylation treatment alone. Interim analysis from the first 28 patients revealed three have now achieved clinical responses (1 partial and 2 marrow complete responses) extending the trial into the second phase. Again, the ability for Pracinostat to achieve clinical responses in the most difficult to treat disease cohorts further proves its impressive clinical efficacy."

MEIP